139543-66-1

Basic information

• Product Name: Benzoic acid, 2-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-, methyl ester
• CAS NO: 139543-66-1
• Molecular Formula: C19H18N2O3
• Molecular Weight: 322.364
• Mol File: 139543-66-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-, methyl ester(139543-66-1)
• EPA Substance Registry System: Benzoic acid, 2-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-, methyl ester(139543-66-1)

Safety Data

• Hazardous Substances Data: 139543-66-1(Hazardous Substances Data)

Upstream product

• 830-96-6 Indole-3-propionic acid 
• 134-20-3 2-carbomethoxyaniline 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 133040-57-0 2-[2-(3-indolyl)ethyl]-3-phenyl-4-(3H)quinazolinone 
• 139543-67-2 3-(3-indolyl)-N-(2-carboxyphenyl)propionamide 

Relevant articles and documents

Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root

From an aqueous decoction of the traditional Chinese medicine “ban lan gen” (the Isatis indigotica root), an antiviral natural product CI - 39 was isolated as an NNRTI (non-nucleoside reverse transcriptase inhibitor) (EC50 = 3.40 μM). Its novel structure was determined as methyl (1-methoxy-1H-indol-3-yl)acetamidobenzoate by spectroscopic data and confirmed by single crystal X-ray diffraction. Through synthesis and structure-activity relationship (SAR) investigation of CI - 39 and 57 new derivatives (24 with EC50 values of 0.06–8.55 μM), two optimized derivatives 10f and 10i (EC50: 0.06 μM and 0.06 μM) having activity comparable to that of NVP (EC50 = 0.03 μM) were obtained. Further evaluation verified that 10f and 10i were RT DNA polymerase inhibitors and exhibited better activities and drug resistance folds compared to NVP against seven NNRTI-resistant strains carrying different mutations. Especially, 10i (EC50 = 0.43 μM) was more active to the L100I/K103N double-mutant strain as compared to both NVP (EC50 = 0.76 μM) and EFV (EC50 = 1.08 μM). The molecular docking demonstrated a possible binding pattern between 10i and RT and revealed activity mechanism of 10i against the NNRTI-resistant strains.

Indole compound with antivirus activity in radix isatidis and derivative of indole compound

The invention discloses an indole compound extracted from radix isatidis shown in a general formula (I) and a derivative of the indole compound, as well as a salt acceptable on pharmacy, a preparation method of the compound, and a medicinal composite. The compound has apparent HIV-resisting activity and influenza virus-resisting activity, and can be used for preparing drugs or healthcare products for resisting HIV or influenza viruses. (The formula is shown in the description.).

3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof

Novel substituted quinazolinones have been found to exhibit specific binding to cholecystokinin (CCK) receptors in the brain and/or peripheral site such as the pancreas and ileum. The quinazolinones are CCK receptor antagonists and find therapeutic applic